<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="35664">Statins</z:chebi> are reported to reduce mortality in patients with <z:hpo ids='HP_0001677'>coronary artery disease</z:hpo> and that mortality benefit might be related to the drugs' antiarrhythmic properties </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: Male rats were fed with or without pravastatin (0.1 mg·kg⁻¹·day⁻¹) for 7 days, and thereafter subjected to 10 min of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> by coronary artery ligation followed by 20 min reperfusion </plain></SENT>
<SENT sid="2" pm="."><plain>Treatment with pravastatin reduced the frequency and duration of <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> and <z:mp ids='MP_0006109'>fibrillation</z:mp> (VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>) and improved the <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> score after reperfusion </plain></SENT>
<SENT sid="3" pm="."><plain>To investigate the rapid effects of pravastatin, isolated perfused rat hearts were subjected to 20 min of global <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> followed by 30 or 60 min of reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with pravastatin (10 nmol/L) from 10 min before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> shortened the total duration of reperfusion-induced VT/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, pravastatin administered from the beginning of reperfusion also exerted antiarrhythmic effects </plain></SENT>
<SENT sid="6" pm="."><plain>These results indicate that pravastatin exerts antiarrhythmic effects not only with daily oral intake but also when administered just before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> or even after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Intracellular calcium ([Ca²⁺](i)) overload and collapse of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> inner membrane potential (Δψ(m)) are associated with the arrhythmogenesis during <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion </plain></SENT>
<SENT sid="8" pm="."><plain>In cultured cardiomyocytes, pretreatment with pravastatin (10 nmol/L) suppressed [Ca²⁺](i) overload and prevented Δψ(m) loss induced by H₂O₂ </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Pravastatin attenuated reperfusion-induced lethal <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Inhibition of [Ca²⁺](i) overload and preserving Δψ(m) may be the mechanisms of the observed antiarrhythmic effects of pravastatin </plain></SENT>
</text></document>